Upcoming - register now:
- Improving cell-based assays and their future in drug discovery
Topics covered will include 3D in vitro models; complex co-culture assays using patient samples; iPSCs; imaging as a method for understanding the impact of a therapeutic; the use of functional genomic screens to aid drug discovery; and in vitro models to support the 3Rs.
- Leveraging Advances in Predesigned Synthetic sgRNAs for Highly Functional and Specific CRISPR-Cas9 Gene Knockout
Synthetic guide RNAs are amenable to chemical modifications, eliminate time-consuming steps of cloning, do not have the inherent immune response and cytotoxicity, and can be readily delivered into cells for high-throughput arrayed screening applications.
- High-Throughput Genome-Wide RNAi Screens: Insights from the Sheffield RNAi Screening Facility
This webinar will provide an overview of high-throughput RNAi screening from the perspective of a dedicated RNAi screening facility.
- A virtual workshop for precise HDR-mediated genome engineering with CRISPR-Cas9
The use of CRISPR-Cas9 to create targeted double-strand breaks in genomic DNA has greatly simplified strategies for precise gene editing using the homology-directed repair (HDR) mechanism.
- A workflow for CRISPR-Cas9 high throughput arrayed screening with synthetic crRNA
There is a rapidly growing interest in using the CRISPR-Cas9 system for functional screening, both as a primary screening tool and as an orthogonal tool for RNAi hit validation.
- Addressing the Pre PCR Analytical Variability of FFPE Samples
Despite technical advances, assessing the accuracy of pre-PCR steps, which include DNA extraction from formalin-fixed paraffin-embedded (FFPE) tissues
- Addressing the Variability of Molecular Assays
Horizon Discovery is a translational company and we have expertise in genome editing, discovery services, and diagnostic reagents.
- Analyzing the combination effects of multi-drug interventions
The increasing size and complexity of data sets from combination studies represent a major challenge in the drug discovery process.
- Arrayed CRISPR libraries for high-throughput functional genomics
Using synthetic crRNA to screen in a one-gene-per-well format
- CRISPR-Cas9: From reagent selection to experimental optimization
The use of CRISPR-Cas9 for gene editing has opened up many new avenues for scientific exploration around gene function.
- CRISPR-Cas9 gene editing with synthetic RNA - from start to finish
The CRISPR-Cas9 system is being widely used for genome engineering in many different biological applications.
- CRISPR engineered human cell lines and types of genomic modifications
Explore through case studies the types of modifications that can be made with CRISPR-Cas9 in human cell lines
- CRISPR Screening From target selection to patient stratification
In a remarkably short time since its development, high-throughput CRISPR screening has revolutionized functional genomics and drug discovery
- CRISPR screening in primary human T cells extending cell type capabilities
Genetic screens are powerful tools to interrogate cell response to drug treatment as well as microenvironment perturbations.
- CRISPR Screening the What Why and How
CRISPR–Cas9 mediated genome editing provides a highly efficient way to probe gene function.
- CRISPRa tools for transcriptional activation studies
The CRISPR-Cas9 system has been adapted to upregulate any gene in its endogenous context, enabling overexpression experiments.
- Exploring inducible systems to inactivate wildtypes
This webinar will describe the level of knockdown that can be achieved with degron-tagged CRISPR interference proteins, how best to deploy dox-inducible Cas9, and various approaches to delete wild-type alleles of genes so as to replace them with inactive alleles that could be applied at scale.
- FISH and IHC Quality Assurance The use of Reference Slides
Clinical laboratories are routinely using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) for accurate assessment of patient samples to determine the gene expression profile of oncogenes
- Getting started with siRNA: considerations & recommendations
This is an introduction to the biological mechanism of RNA interference (RNAi) and experimental application of short, interfering RNA (siRNA).
- High-throughput CRISPR-Cas9 Genome Engineering in Primary T Cells
Learn how to optimize CRISPR-Cas9 gene editing in primary T cells using RNPs, and how this is being employed to understand HIV pathogenesis
- How CRISPR-Cas9 screening will revolutionize your drug development programs
A powerful tool for drug target ID and validation, understanding drug mechanisms of action, and patient stratification.
- How to identify key genes with CRISPR-Cas9 and shRNA screens
The ability to modulate gene expression at genome scale has revolutionized functional genomics in mammalian cells.
- How to use CRISPR-Cas9 for knockout, knock-in, and gene activation
The rapid adoption and ease of use of CRISPR-Cas9 has driven the development of applications for gene knockout, precise gene editing, and transcriptional regulation.
- How to Validate and Verify the Accuracy of your Clinical Laboratory Procedures
In the webinar we will discuss the latest developments surrounding the FDA and LDTs and will present examples of how HDx Reference Standards could help your laboratory improve the accuracy of your assay.
- Improve CRISPR-Cas9 experiments with rationally designed guide RNAs
The CRISPR-Cas9 system introduces double-strand DNA breaks at a specific locus in the genome by using a complex of the Cas9 nuclease with either a chimeric single guide RNA (sgRNA) or two short RNAs (a CRISPR RNA (crRNA) and a trans-activating RNA (tracrRNA)).
- Optimizing homology-directed repair (HDR) results with CRISPR-Cas9
CRISPR-Cas9 has increased the accessibility of genome engineering due to its ease of use and ability to cause double-strand breaks (DSBs) at almost any locus of interest
- Phenotypic CRISPR screening beyond cell viability to study complex genetic interactions
CRISPR screening, whether using knockout, activation, or inhibition approaches, have become essential tools for drug discovery
- Power Up CRISPRi and CRISPRa Tools for Genome-Wide Screening
Ben joined Horizon in 2013 to expand and develop Horizon’s functional genomic screening capability and to lead a major research alliance in synthetic lethal target discovery.
- Pro-Active CHO Cell Line Development for Bioproduction
After over 25 years of using CHO cells for the production of biotherapeutics, the majority of production gains have come through improvement to medias and feeds.
- Resolving Ambiguity in Target ID Screens CRISPR Cas9 Based Essentiality Profiling
The CRISPR–Cas9 system can be used to disrupt specific genes leading to genetic knockouts.
- Systematic application of the CRISPR toolkit
View our webinar on Dual CRISPRi and CRISPRa screening which can power up your drug discovery and development programs, improving your rate of target discovery:
- The Effect of Formalin on Clinical Diagnostics
The use of formalin fixative stems from its ability to cross-link proteins, however, it has also been reported to induce methylol modifications and acid-mediated hydrolysis which can confound genotyping analysis. Similarly, variability in the fixation time, delay of fixation and type of fixation effect tumor biopsies and subsequent sequencing.
- Tools for Knockdown of Long Noncoding RNA
Long noncoding RNAs (lncRNAs) are defined as RNAs that do not encode protein and are longer than 200 nucleotides
- Understanding and Controlling for Sample and Platform Biases in NGS Assays
In this webinar, we will focus on next-generation sequencing and discuss: the effect of formalin treatment on molecular protocols and how it can be controlled, how to select the sequencing platform most appropriate for your sample, evaluation of whether structural variants are being detected by your assay and how Reference Standards can be used in each validation parameter.
- Using Reference Standards to Validate your NGS Oncology Workflow
We are currently at an exciting precipice in clinical oncology management, where an increased rate of biomarker identification is driving the development of new targeted therapies, coupled with advances in sequencing technology capability.